QUANTA-SYSTEM
Quanta System proudly opens the door to the New Year by unleashing the ultimate innovation in the picosecond laser technologies: Discovery PICO with VarioPulse Technology®. An unprecedented level of precision and versatility in a device that allows you to select the picosecond pulse-duration to personalize the treatments to meet the unique needs of each person.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130556983/en/
Pico Filling Treatment - skin rejuvenation (Photo: Business Wire)
Quanta System has always been committed to follow the evolving needs of the market and to listen and understand the needs of its customers. Discovery PICO VarioPulse Technology® represents a significant leap forward in the world of aesthetic medicine.
Featuring Pico Boost technology that can deliver up to 1.8GW of laser power perfectly controlled by the VarioPulse Technology®, this next-generation device welcomes you to 3 cutting-edge customized treatments that are precisely designed to perform tattoo removal and skin revitalization at their best.
Pico Tune-Ink, the adaptable treatment that removes tattoo ink of a wide variety of colour and complexity;
Pico Filling, the no down-time treatment that revitalizes the skin from within and improve its appearance;
Pico Plasma, the all round skin remodeling treatment that targets scars and acne scars.
Commenting on this major launch, Girolamo Lionetti, CEO of Quanta System, expresses his excitement, "We are thrilled to bring this new technology to the aesthetic world. Our primary goal of improving people's quality of life is greatly enhanced by continuing to work alongside our valued partners, the physicians, and providing patients with more and more customized treatments.”
This is just the first step of a new era laser roadmap focused on delivering the superior user experience and patient satisfaction that the market has been waiting for.
For more information about Discovery PICO VarioPulse Technology®, visit our website www.quantasystem.com or come to discover it in person at IMCAS Booth U322 Level 3 - February 1st -3rd 2024.
About Quanta System
For almost forty years Quanta System, a 100% Italian company distributed worldwide, is the reference point for the research, designing and manufacture of state-of-the-art laser systems for surgery, dermatology and aesthetic medicine and the conservation of art works.
In 2004 the company joins El.En. SpA, leader on the laser market listed on the Euronext STAR Milan ("STAR") of the Italian Stock Exchange and a partner of reference for health facilities, Institutions and Entities engaged in scientific and research projects at a global level.
Designed to be used by doctors, specialised operators and restorers, today the Quanta System lasers represent the "Gold Standard" thanks to a wide range of applications.
The laser systems are entirely manufactured in Italy: from Research & Development to production, the entire process takes place in the company's headquarters in Samarate (in the province of Varese).
Quanta System is a trusted partner, day in day out, of all doctors in every part of the world thanks to its ability to listen, its straightforward debates and the creation of new systems that increasingly meet the real needs of professionals so they can provide better care for their patients.
A constantly evolving company that has managed to update its production so that it has always managed to satisfy the developing needs of its time, without losing sight of its primary objective: contributing to the improvement of people's quality of life.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130556983/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 09:00:00 CET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 08:58:00 CET | Press release
Benefit Street Partners and Alcentra align under a single, refreshed BSP brand.Move reflects client demand for a specialist, integrated and global credit platform.Franklin Templeton’s alternative credit platform on track to exceed $100bn in 2026.BSP outlines further growth plans including expansion in the Middle East and Asia.New research says 51% of institutional investors will increase credit allocation in 2026.81% of institutions say a specialist focus on credit is the top attribute for performance. Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 08:00:00 CET | Press release
In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year historyExcluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 08:00:00 CET | Press release
Virtual wind PPA with guarantees of origin to decarbonize Syngenta's plants in Europe Important element in carbon reduction journey for Syngenta AG Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Hea
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity26.1.2026 08:00:00 CET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom